Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20

ABBOTT LABORATORIES

2025-Q2 EPS reported $1.77 revenue$21,500,000,000

GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.
Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.
Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.
Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.